• Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality
• Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]
• Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven …